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Diphtheria, Tetanus, and Pertussis 
DTaP/DT and Tdap/Td Vaccines
Chapters 7, 21, and 16
Diphtheria  
Disease
1
 A toxin-mediated disease caused by Corynebacterium diphtheriae
 Usually produces exudate and membrane involving pharynx and tonsils
 Complications attributable to toxin – severity generally related to 
extent of local disease
 Most complications are myocarditis and neuritis
 Death in 5% to 10% of cases
Diphtheria 
Tonsillar 
diphtheria
 Incubation period 2–5 days (range: 1–10 days)
 May involve any mucous membrane
 Classified based on site of disease 
• Anterior nasal
• Pharyngeal and tonsillar
• Laryngeal
• Cutaneous
• Ocular
• Genital
Diphtheria Clinical Features 
Diphtheria in the Late 19th–Early 20th Century
Number of reported diphtheria cases -- United States, 1980-2015
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Source: National Notifiable Diseases Surveillance System
Tetanus  
Disease
2
 A toxin-mediated disease caused by Clostridium tetani
 Anaerobic gram-positive, spore-forming bacteria
 Spores found in soil, animal feces
 Two exotoxins produced with growth of bacteria
• Tetanospasmin responsible for clinical manifestations of tetanus
Tetanus 
 Incubation period: 8 days (range: 3–21 days)
 Three clinical forms: local (uncommon), cephalic (rare), generalized 
(most common)
 Generalized tetanus: descending pattern of trismus (lockjaw), stiffness 
of the neck, difficulty swallowing, rigidity of abdominal muscles
• Spasms continue for 3–4 weeks
• Complete recovery may take months
 Neonatal tetanus
• Generalized tetanus in newborn infant
• Infant born without protective passive immunity
• 58,000 neonates died in 2010 worldwide
Tetanus Clinical Features 
• Required 57 days of inpatient acute care, including 47 days 
in the intensive care unit
• The inpatient charges totaled $811,929 (excluding air 
transportation, inpatient rehabilitation, and ambulatory 
follow-up costs)
Annual incidence* of and deaths due to tetanus -- United 
States, 1900-2015
Source: CDC. National Notifiable Disease Surveillance System
Sources: National Notifiable Diseases Surveillance System and passive reports to the Public Health Service 
* Per 100,000 population
Pertussis  
Disease
3
 Acute infectious disease caused by Bordetella pertussis
 Outbreaks first described in 16th century
 Bordetella pertussis isolated in 1906
 Estimated 195,000 deaths worldwide in 2008
Pertussis
 Incubation period: 7–10 days (range: 4–21 days)
 Insidious onset, similar to the common cold with nonspecific cough
 Fever usually minimal throughout course of illness
 Catarrhal stage 
• 1–2 weeks
 Paroxysmal cough stage 
• 1–6 weeks
 Convalescence 
• Weeks to months
Pertussis Clinical Features 
Reported NNDSS pertussis cases: 1922-2015*
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*2015 data are provisional
SOURCE: CDC, National Notifiable Diseases Surveillance System and Supplemental Pertussis Surveillance System and 1922-1949, passive reports to the Public Health Service 
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Reported Pertussis Incidence by Age Group: 1990-2016*
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SOURCE: CDC, National Notifiable Diseases Surveillance System and Supplemental Pertussis Surveillance System
Pertussis Deaths in the United States, 2012–2018
https://www.cdc.gov/pertussis/surv-reporting.html
Age at onset
Less than 
12 months
12 months 
and older Total
59
(72%)
23
(28%) 82
 20,762 pertussis cases reported in the U.S. in 2015, 15,737 cases in 
2016
• >50% of cases in those 11 years and older
 Infection may be asymptomatic, or may present as classic 
pertussis
 Disease often milder than in infants and children
• Persons with mild disease may transmit the infection 
 Older persons and household contacts often source of infection for 
infants and children 
Why Adolescents and Adults Need Pertussis Vaccine
Difficulty sleeping
Urinary incontinence
Pneumonia
Rib fracture
Plus: 
• Medical costs
• Missed school and work 
• Impact on public health system
Pertussis Complications Among Adolescents and Adults
Vaccinate Throughout a Lifetime! 
Birth
DTaP Tdap Td 
DTaP/DT
Vaccine
4
DTaP-Containing Vaccine Products
 Components: DTaP, HepB, and IPV 
 Licensed for:
• Children 6 weeks through 6 years of age
• Doses 1 through 3
 Not approved for doses 4 or 5
 Can be given to infants who received a birth dose of hepatitis B vaccine 
• Total of 4 doses of HepB vaccine 
DTaP-HepB-IPV (Pediarix)
 Components: DTaP,  IPV, and Hib
 Licensed for:
• Children 6 weeks though 4 years of age 
• Doses 1 through 4
 Not approved for the 5th dose of DTaP series or for children older than 
5 years
DTaP-IPV/Hib (Pentacel)
DTaP-IPV/Hib (Pentacel)
 Must be reconstituted (mixed) prior to administration 
 Use ONLY the manufacturer-supplied vaccine diluent (DTaP-IPV)
Hib vaccine DTaP-IPV diluent
+ =
Pentacel vaccine 
 Components: DTaP and IPV
 Licensed for:
• Children 4 through 6 years of age 
• Dose 5 only 
 Do NOT use for doses 1 through 4 or for children younger than 4 years 
of age
DTaP-IPV (Kinrix and Quadracel) 
 Components: DTaP, IPV, Hib, HepB
 Licensed for:
• Children 6 weeks through 4 years
• 3-dose series (2, 4, 6 months of age)
 Do NOT use for 4th or 5th doses
DTaP, IPV, Hib, HepB (Vaxelis)
Administer the Right Vaccine! 
Order, administer, and document the correct vaccine! 
Product (mfr) Component(s) Use for ages
Use for DTaP
doses  Route
Daptacel (SP) DTaP 6 wks thru 6 yrs 1 thru 5 IM
Infanrix (GSK) DTaP 6 wks thru 6 yrs 1 thru 5 IM
Pediarix (GSK) DTaP-HepB-IPV 6 wks thru 6 yrs 1 thru 3 IM
Pentacel (SP) DTaP-IPV/Hib 6 wks thru 4 yrs 1 thru 4 IM
Kinrix (GSK),
Quadracel (SP) DTaP-IPV 4 thru 6 yrs 5 IM
Vaxelis (Merck) Dtap-IPV-Hib-HepB 6 wks thru 4 years 3-dose series IM
 Whenever feasible, the same DTaP vaccine should be used for all doses 
of the series
 Limited data suggest that  “mix and match” DTaP schedules do not 
adversely affect safety and immunogenicity
 If vaccine used for earlier doses is not known or not available, any 
brand may be used to complete the series
Interchangeability of Different Brands of DTaP Vaccine
Primary DTaP  Schedule
https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
Dose Routine Age
Minimum 
Interval to Next Dose 
Primary 1 2 months 4 weeks
Primary 2 4 months 4 weeks
Primary 3 6 months 6 months
Primary 4 15–18 months
 Routinely recommended at 15 through 18 months
 May be given earlier if:
• Child is at least 12 months of age and
• At least 6 months since DTaP dose 3 and
• Child is unlikely to return at 15 through 18 months of age
Fourth DTaP Dose
Fifth DTaP Dose
 Administer a 5th dose of DTaP when the 4th dose was given before
age 4 years
 All DTaP products are approved for use for the 5th dose except: 
• Pediarix (DTaP-HepB-IPV)
• Pentacel (DTaP-IPV/Hib)
 Given as a 3- or 4-dose series
 DT should only be used for children with a true contraindication to 
pertussis vaccine 
Diphtheria and Tetanus Toxoid 
DT Vaccine
 First dose of DT at younger than 1 year of age 
• Total of 4 doses
 First dose of DT at 1 year of age or older
• Total of 3 doses
 4th or 5th dose at school entry not needed if pertussis vaccine is not 
being administered
Pediatric DT Schedule
 Severe allergic reaction to vaccine component or following a prior dose
 Encephalopathy not due to another identifiable cause occurring within 
7 days after vaccination
DTaP Contraindications
 Moderate or severe acute illness
 Progressive or unstable neurologic disorder, including infantile spasms, 
uncontrolled seizures, or progressive encephalopathy
 Guillain-Barré syndrome <6 weeks after previous dose of tetanus-
toxoid-containing vaccine
 History of Arthus-type hypersensitivity reactions after a previous dose 
of tetanus- or diphtheria-toxoid-containing vaccines
DTaP Precautions
 Temperature of 105° F (40.5° C) or higher within 48 hours with no other identifiable 
cause
 Collapse or shock-like state (hypotonic hyporesponsive episode) within 48 hours
 Persistent, inconsolable crying lasting 3 hours or more, occurring within 48 hours
 Convulsions with or without fever occurring within 3 days
 Family history of seizures, SIDS, adverse event after pertussis vaccination
 Stable neurological condition(s)
DTaP Former Contraindications – No Longer Applicable
 Local reactions 
(pain, redness, swelling)
20%–40%
 Temperature of 101° or higher 3%–5%
 More severe adverse reactions Not common
DTaP Adverse Reactions
 Local adverse reactions and fever increased 
 Reports of swelling of entire limb
• Self-limited and resolves without sequelae
 Limb swelling after 4th dose NOT a contraindication to 5th dose
Adverse Reactions 
Following the 4th and 5th DTaP Doses
Tdap/Td
Vaccine
2
Tdap and Td Vaccines
Vaccine product Age indications
Tdap vaccines
Boostrix 10 years and older
Adacel 10–64 years
Td vaccines
TDVAX 7 years and older
TENIVAC 7 years and older
Clinical 
Considerations
3
ACIP Tdap/Td Vaccine Recommendations
*Off-label recommendation: Adacel for persons 65 years of age and older  
 Routinely recommended at 11–12 years of age 
 Catch-up adolescents 13 years of age and older who were not 
vaccinated 
Tdap Recommendations: Adolescent  
MMWR 67(2):1–44 
 Administer Tdap vaccine to persons 19 years of age and older who 
were NOT previously vaccinated and to those with unknown 
vaccination status 
• Persons who were vaccinated with Tdap during adolescence (or at another time) = 
previously vaccinated, including: 
o Health care personnel 
o New fathers
o Close contacts of newborns 
o Day care workers or babysitters 
• No additional doses are recommended 
Tdap Recommendations: Adults  
MMWR 67(2):1–44 
 Children who have not completed a primary series 
• Tdap should be administered first
• If additional doses are needed, Td should be administered 
 Those who are not fully immunized against pertussis (i.e., did not 
complete a series of pertussis-containing vaccine before their 7th
birthday) should receive a single dose of Tdap
• If additional doses are needed, Td should be administered
 Adolescents who received Tdap inadvertently or as part of the catch-up 
series between 7–10 years of age should be given the routine 
adolescent Tdap dose at 11–12 years of age
Tdap Recommendations: Children 7 through 10 Years of Age*
*Off-label ACIP recommendation
MMWR 67(2):1–44 
 Administer a dose of Tdap during each pregnancy, regardless of the 
patient's prior history of receiving the vaccine
 Tdap should be administered between 27 and 36 weeks’ gestation, 
although it may be given at any time during pregnancy.  
• Currently available data suggest that vaccinating earlier in the 27- through 36-week 
time period will maximize passive antibody transfer to the infant
Tdap Recommendations: Pregnant Women 
*Off-label ACIP recommendation  MMWR 67(2):1–44 
Vaccination coverage for pregnant 
women:
• 2010 and earlier <1% 
• 2013 28% 
• 2015 53%
96% of Tdap vaccinations were 
administered in physicians’ offices or 
clinics
Tdap and Pregnant Women 
MMWR 66(41):1105–1108  
Maternal Tdap Vaccination is Very Effective in Prevention of 
Infant Pertussis Infection
Definitions
Vaccine effectiveness 
(95% confidence intervals)
Infant age at 
pertussis onset
Mother gestational age 
received Tdap
United Kingdom
Observational,1
screening method
91% (83–95%) Younger than
3 months
At least 28 days before birth*
Case-Control,2 
retrospective
91% (77–97%), unadjusted
93% (81–97%), adjusted¶
Younger than
months
Cases: 31.5 weeks (range, 28–38)
Controls: 33 weeks (range, 26–38)
United States
Cohort,3
retrospective
85% (33–98%) Younger than
2 months
27–36 weeks
Case-Control,4
retrospective
78% (44–91%) Younger than 
2 months
27–36 weeks
*2012 UK recommendation: Tdap between 28 and 38 weeks
¶Adjusted for sex, geographical area, and birth period
1Amirthalingam G, et al. 2014; 2Dabrera G, et al. 2015; 3Winter K, et al. 2016; 4CDC, unpublished
 Data reassuring on 2 doses of Tdap
 Data and experience with tetanus toxoid vaccine suggest no excess risk 
of adverse events
o ~5% of women would receive 4 or more doses
 CDC provides ongoing monitoring to address concerns about the safety 
of Tdap given during subsequent pregnancies
ACIP Conclusions: Safety of Tdap for Every Pregnancy
 Previously unvaccinated EVER or vaccination status unknown–
administer Tdap
 Previously vaccinated persons – Tdap is NOT indicated 
• Including mothers, fathers, siblings, and grandparents 
• Any previous, documented dose counts 
Postpartum Women and Close Contacts of Infants  
 All adolescents and adults should have documentation of having 
received a primary series of DTaP, DTP, DT, Tdap, or Td 
 Persons without documentation who have never been vaccinated or 
have unknown status should receive a 3-dose primary series 
 One dose should be Tdap, preferably the first 
Tdap for Persons Without History of DTP or DTaP
 Preferred schedule:
• Dose 1 Tdap
• Dose 2 Td at least 4 weeks after dose 1
• Dose 3 Td at least 6 months after dose 2
• Booster Td every 10 years
Tdap for Persons Without History of DTP or DTaP
 ACIP recognizes the increasing burden of pertussis and the need for an 
effective strategy to reduce this burden
 A study evaluating additional doses of Tdap administered at either a 5-
or 10-year interval suggested that the reduction in pertussis disease 
burden would be limited
 ACIP concluded that the data do not support a general 
recommendation for a routine second dose of Tdap, and that the public 
health impact of routinely recommending a second dose of Tdap would 
be limited 
No Additional Doses of Tdap for the General Population
MMWR 67(2):1–44 
Tdap and Health Care Personnel
 Previously unvaccinated HCP should receive a single dose of Tdap as 
soon as feasible, regardless of time since last Td dose
 After receipt of 1 dose of Tdap, health care personnel should receive 
routine Td booster immunizations according to the recommended 
schedule
 Additional doses of Tdap are not recommended for previously 
vaccinated HCP*
Tdap and Health Care Personnel (HCP)
*Except pregnant women 
MMWR 2006;55(RR-17):1–37
Tetanus Prophylaxis 
MMWR / April 27, 2018 / Vol. 67 / No. 2 - https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6702a1-H.pdf
 Severe allergic reaction to vaccine component or following a prior dose
 Encephalopathy not due to another identifiable cause within 7 days of 
administration of a pertussis-containing vaccine
Tdap Contraindications
 History of Guillain-Barré syndrome within 6 weeks after a prior dose of 
tetanus toxoid-containing vaccine
 Progressive neurologic disorder until the condition has stabilized
 History of a severe local reaction (Arthus reaction) following a prior 
dose of a tetanus- and/or diphtheria-toxoid-containing vaccine
 Moderate or severe acute illness
Tdap Precautions
 Local reactions (pain, redness, swelling)
• 21– 66% 
 Temp of 100.4°F or higher
• 1.4% 
 Adverse reactions occur at approximately the same rate as Td alone 
(without acellular pertussis vaccine) 
Tdap/Td Adverse Reactions
